Cargando…
Metals in Imaging of Alzheimer’s Disease
One of the hallmarks of Alzheimer’s disease (AD) is the deposition of amyloid plaques in the brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the pathology. Timely diagnostics of amyloid formations allows identifying AD at an early stage and initiating inhibitor th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730413/ https://www.ncbi.nlm.nih.gov/pubmed/33276505 http://dx.doi.org/10.3390/ijms21239190 |
_version_ | 1783621678550482944 |
---|---|
author | Krasnovskaya, Olga Spector, Daniil Zlobin, Alexander Pavlov, Kirill Gorelkin, Peter Erofeev, Alexander Beloglazkina, Elena Majouga, Alexander |
author_facet | Krasnovskaya, Olga Spector, Daniil Zlobin, Alexander Pavlov, Kirill Gorelkin, Peter Erofeev, Alexander Beloglazkina, Elena Majouga, Alexander |
author_sort | Krasnovskaya, Olga |
collection | PubMed |
description | One of the hallmarks of Alzheimer’s disease (AD) is the deposition of amyloid plaques in the brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the pathology. Timely diagnostics of amyloid formations allows identifying AD at an early stage and initiating inhibitor therapy, delaying the progression of the disease. However, clinically used radiopharmaceuticals based on (11)C and (18)F are synchrotron-dependent and short-lived. The design of new metal-containing radiopharmaceuticals for AD visualization is of interest. The development of coordination compounds capable of effectively crossing the blood-brain barrier (BBB) requires careful selection of a ligand moiety, a metal chelating scaffold, and a metal cation, defining the method of supposed Aβ visualization. In this review, we have summarized metal-containing drugs for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer’s disease. The obtained data allow assessing the structure-ability to cross the BBB ratio. |
format | Online Article Text |
id | pubmed-7730413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77304132020-12-12 Metals in Imaging of Alzheimer’s Disease Krasnovskaya, Olga Spector, Daniil Zlobin, Alexander Pavlov, Kirill Gorelkin, Peter Erofeev, Alexander Beloglazkina, Elena Majouga, Alexander Int J Mol Sci Review One of the hallmarks of Alzheimer’s disease (AD) is the deposition of amyloid plaques in the brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the pathology. Timely diagnostics of amyloid formations allows identifying AD at an early stage and initiating inhibitor therapy, delaying the progression of the disease. However, clinically used radiopharmaceuticals based on (11)C and (18)F are synchrotron-dependent and short-lived. The design of new metal-containing radiopharmaceuticals for AD visualization is of interest. The development of coordination compounds capable of effectively crossing the blood-brain barrier (BBB) requires careful selection of a ligand moiety, a metal chelating scaffold, and a metal cation, defining the method of supposed Aβ visualization. In this review, we have summarized metal-containing drugs for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer’s disease. The obtained data allow assessing the structure-ability to cross the BBB ratio. MDPI 2020-12-02 /pmc/articles/PMC7730413/ /pubmed/33276505 http://dx.doi.org/10.3390/ijms21239190 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Krasnovskaya, Olga Spector, Daniil Zlobin, Alexander Pavlov, Kirill Gorelkin, Peter Erofeev, Alexander Beloglazkina, Elena Majouga, Alexander Metals in Imaging of Alzheimer’s Disease |
title | Metals in Imaging of Alzheimer’s Disease |
title_full | Metals in Imaging of Alzheimer’s Disease |
title_fullStr | Metals in Imaging of Alzheimer’s Disease |
title_full_unstemmed | Metals in Imaging of Alzheimer’s Disease |
title_short | Metals in Imaging of Alzheimer’s Disease |
title_sort | metals in imaging of alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730413/ https://www.ncbi.nlm.nih.gov/pubmed/33276505 http://dx.doi.org/10.3390/ijms21239190 |
work_keys_str_mv | AT krasnovskayaolga metalsinimagingofalzheimersdisease AT spectordaniil metalsinimagingofalzheimersdisease AT zlobinalexander metalsinimagingofalzheimersdisease AT pavlovkirill metalsinimagingofalzheimersdisease AT gorelkinpeter metalsinimagingofalzheimersdisease AT erofeevalexander metalsinimagingofalzheimersdisease AT beloglazkinaelena metalsinimagingofalzheimersdisease AT majougaalexander metalsinimagingofalzheimersdisease |